Please login to the form below

Not currently logged in
Email:
Password:

Merck halts work on pain drug

Merck & Co and Canadian-headquartered Neuromed Pharmaceuticals have stopped the development of an experimental pain drug that disappointed in clinical trials

US-based Merck & Co and Canadian-headquartered Neuromed Pharmaceuticals have stopped the development of an experimental pain drug that disappointed in clinical trials.

Neuromed said in press statement: "NMED-160 (MK-6721) did not demonstrate the ideal pharmaceutical characteristics considered necessary to advance the compound further in development."

The drug is an N-type calcium channel blocker which was designed to interfere with the transmission of pain signals. Neuromed added that itself and Merck are still trying to develop similar products.

Merck entered into the agreement with Neuromed in March 2006, which was initially worth USD 475m to the company. Since Merckís Vioxx was withdrawn from the world market, Merck has been trying to find painkillers to fill its pipeline gap for this indication.

9th August 2007

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Oxford PharmaGenesis

Oxford PharmaGenesis is an independently owned HealthScience communications consultancy, providing services to the healthcare industry, professional societies and patient groups....

Latest intelligence

When is an agency not an agency?
The PR Week UK Top 150 Consultancies prompts anticipation and curiosity. But can a virtual collective of freelancers fairly be compared and ranked against conventional agencies?...
Why big pharma needs to be braver
The last few years have seen the pharmaceutical industry undergo a rapid metamorphosis in the face of unprecedented change, but communications are one area that still needs an injection of...
Leveraging Real-World Evidence for Cell and Gene Therapies
Regulators and reimbursement bodies are increasingly turning to real-world evidence (RWE) to understand the long-term value of drugs, in particular novel therapies. Here, Mariam Bibi, Senior Director, Global RWE at...